Table 1.
Characteristics of the study population of 5-year childhood cancer survivors treated with hematopoietic stem cell transplantation in Switzerland, N = 74.
| Sociodemographic and lifestyle characteristics | n (%) |
|---|---|
| Sex, male | 43 (58) |
| Ethnicity, white | 72 (97) |
| Age at first lung function test, median years (IQR) | 9.9 (7.9–14.0) |
| Age at last lung function test, median years (IQR) | 16.2 (14.2–20.0) |
|
Smoking statusa Active smoking Former active smoking Passive smoking Never active smoking |
4 (5) 5 (7) 32 (43) 33 (45) |
| Clinical characteristics | |
| Age at diagnosis, median years (IQR) | 7.4 (3.5–12.2) |
| Time between diagnosis and HSCT, median years (IQR) | 0.8 (0.5–2.6) |
| Follow-up, median years (IQR)b | 9.4 (6.1–12.3) |
|
Era of diagnosis 1980–1990 1991–2000 2001–2010 |
8 (11) 24 (32) 42 (57) |
|
Cancer diagnosis according to ICCC-3 I: Leukemia II: Lymphoma Otherc |
51 (69) 12 (16) 11 (15) |
| Relapse | 41 (55) |
| Treatment characteristics | |
| Lung-toxic chemotherapeutics, dose, mg/m2 (IQR) | |
| Busulfan (n = 25) | 422 (324–470) |
| Carmustine (n = 5) | 300 (300–300) |
| Lomustine (n = 1) | 190 |
| Bleomycin (n = 4) | 41 (30–46) |
| Radiotherapy involving the thoraxd | 52 (70) |
| Conditioning containing TBI | 39 (53) |
| Thoracic surgerye | 10 (14) |
| Transplant characteristics | |
| Stem cell donor | |
| Autologous | 24 (32) |
| Allogeneic | 50 (68) |
| HLA identical sibling / HLA matched (un-)related donor | 29 (58) |
| HLA mismatch (un-)related / haploidentical | 11 (22) |
| Missing | 10 (20) |
aFor categorization of smoking status see Supplementary Material.
bTime between diagnosis and last pulmonary function test.
cOther tumors include: tumor of the central nervous system (n = 1), retinoblastoma (n = 1), malignant bone tumor (n = 5), soft tissue sarcoma (n = 3), malignant germ cell tumor (n = 1), neuroblastoma (n = 1).
dThoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-)mantle field, TBI and additionally upper abdomen, thoracic spine, and craniospinal irradiation.
eThoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall surgery, rib resection, lobectomy, pulmonary metastasectomy and wedge resection.